Risk of failing both methotrexate and mycophenolate mofetil from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial

BACKGROUND: The antimetabolites methotrexate (MTX) and mycophenolate mofetil (MMF) are commonly used as initial corticosteroid-sparing treatment for uveitis. There is little data examining risk factors for failing both MTX and MMF. The objective of this study is to determine risk factors for failing...

Descripción completa

Detalles Bibliográficos
Autores principales: Reddy, Amit K., Miller, D. Claire, Sura, Amol A., Rathinam, SR, Gonzales, John A, Thundikandy, Radhika, Kanakath, Anuradha, Murugan, Bala, Vedhanayaki, Rajesh, Lim, Lyndell L., Suhler, Eric B., Doan, Thuy, Al-Dhibi, Hassan A., Goldstein, Debra A., Arellanes-Garcia, Lourdes, Acharya, Nisha R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256664/
https://www.ncbi.nlm.nih.gov/pubmed/37294447
http://dx.doi.org/10.1186/s12348-023-00350-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256664/
https://www.ncbi.nlm.nih.gov/pubmed/37294447
http://dx.doi.org/10.1186/s12348-023-00350-5

Ejemplares similares